Several types of myeloid cell are resident in the CNS. In the steady state, microglia are present in the CNS parenchyma, whereas macrophages reside in boundary regions of the CNS, such as perivascular spaces, the meninges and choroid plexus. In addition, monocytes infiltrate into the CNS parenchyma from circulation upon blood-brain barrier breakdown after CNS injury and inflammation. Although several markers, such as CD11b and ionized calcium-binding adapter molecule 1 (Iba1), are frequently used as microglial markers, they are also expressed by other types of myeloid cell and microglia-specific markers were not defined until recently. Previous transcriptome analyses of isolated microglia identified a transmembrane lectin, sialic acid-binding immunoglobulin-like lectin H (Siglec-H), as a molecular signature for microglia; however, this was not confirmed by histological studies in the nervous system and the reliability of Siglec-H as a microglial marker remained unclear.
and neuronal degeneration/regeneration after neuronal injury (Gamo et al., 2008; Kobayashi, Konishi, Takai, & Kiyama, 2015; Konishi, Namikawa, & Kiyama, 2006; Kroner et al., 2014) . Although microglia are a well-known type of CNS myeloid cell, other types of myeloid cell also reside at the boundaries of the CNS (Galea et al., 2005; Goldmann et al., 2016; Prinz & Priller, 2014; Prinz, Erny, & Hagemeyer, 2017) , including perivascular macrophages (MU, pvMU) in the perivascular space around medium-or large-sized vessels, meningeal MU (mMU) in the meninges, and choroid plexus MU (cpMU) in the choroid plexus. In addition to these "CNS-associated MU", monocytes infiltrate into the CNS parenchyma from the blood circulation upon blood-brain barrier breakdown under injury or inflammatory conditions (King, Dickendesher, & Segal, 2009; Mildner et al., 2009; Saederup et al., 2010; Varvel et al., 2016) .
Several molecules including CD11b and ionized calcium-binding adapter molecule 1 (Iba1) were established as microglial markers, and antibodies against CD11b and Iba1 were frequently used for immunohistochemical identification of microglia (Ito et al., 1998; Robinson, White, & Mason, 1986) . However, CD11b and Iba1 are widely expressed by myeloid cell types (Ajami, Bennett, Krieger, McNagny, & Rossi, 2011; Greter, Lelios, & Croxford, 2015; Prinz & Priller, 2014; Prinz, Priller, Sisodia, & Ransohoff, 2011) , meaning that the antibodies cannot discriminate microglia from CNS-associated MU and CNSinfiltrating monocytes by immunohistochemistry. For gene targeting of microglia, gene loci or promoter/enhancer regions of integrin subunit alpha M (Itgam) (encoding CD11b), colony-stimulating factor 1 receptor (Csf1r) and C-X3-C motif chemokine receptor 1 (Cx3cr1) were utilized (Boillee et al., 2006; Jung et al., 2000; Pfrieger & Slezak, 2012; Sasmono et al., 2003) . However, microglia-specific targeting was not achieved because these genes are also expressed by other myeloid populations (Goldmann et al., 2016; Wieghofer, Knobeloch, & Prinz, 2015) . Therefore identification of microglia-specific molecules, which are not expressed by other myeloid species, has been pursued.
Several studies have used transcriptome analysis to determine the molecular signature of microglia, resulting in the identification of molecules that are highly expressed by microglia but not by other myeloid cells (Bedard, Tremblay, Chernomoretz, & Vallieres, 2007) ; Butovsky et al., 2014; Chiu et al., 2013; Gautier et al., 2012; Hickman et al., 2013; Wes, Holtman, Boddeke, Moller, & Eggen, 2016) . Among the molecules identified, the expression of transmembrane protein 119 (TMEM119) (Bennett et al., 2016) , Sall1 (Buttgereit et al., 2016) and P2Y 12 (Mildner, Huang, Radke, Stenzel, & Priller, 2017) histologically discriminated microglia from CNS-associated MU or CNS-infiltrating monocytes. Although expression of these molecules is restricted to microglia in the CNS, these markers are not fully specific. For example, TMEM119 expression is absent in immature microglia (Bennett et al., 2016) , Sall1 is abundantly expressed in neuronal/glial progenitor cells during development (Buttgereit et al., 2016; Harrison, Nishinakamura, Jones, & Monaghan, 2012) , and P2Y 12 shows decreased/diminished expression in activated microglia (Amadio et al., 2014; Haynes et al., 2006; Mildner et al., 2017) .
In this study, we focused on a transmembrane lectin, sialic acidbinding immunoglobulin-like lectin H (Siglec-H), which is known as a marker for plasmacytoid dendritic cells (pDCs) in the immune system (Blasius, Cella, Maldonado, Takai, & Colonna, 2006; Zhang et al., 2006) .
Previous transcriptome and flow cytometric studies on isolated cells
suggested Siglec-H as a microglia-specific molecule that was not expressed by peripheral myeloid cells, such as circulating monocytes and peripheral MU (Bedard, Tremblay, Chernomoretz, & Vallieres, 2007) ; Butovsky et al., 2014; Chiu et al., 2013; Gautier et al., 2012; Hickman et al., 2013) . However, no immunohistochemical studies of the nervous system were performed, and marker specificity of Siglec-H, for instance, for CNS-associated MU and CNS-infiltrating monocytes, remained unexplored. Here we demonstrated microglia-specific expression of Siglec-H, including during developmental stages and under injury conditions. in any CNS region due to unknown mechanisms (data not shown). This is consistent with the lack of EGFP expression in pDCs described in our previous study (Takagi et al., 2011) . C-C chemokine receptor type 2 (Ccr2) RFP/RFP knock-in mice on a C57BL/6J background were obtained from The Jackson Laboratory (stock number: 017586) (Saederup et al., 2010) . Embryonic day (E)17, and male postnatal day (P)0, 7, 14, 28, and 8-12-week-old (W) (adult) mice were used. This study was approved by the local animal ethics committee of Nagoya University (approval numbers: 25107, 26181, 27204, and 28303 (Zimmermann, 1983) . All efforts were made to minimize the number of animals used and their suffering.
| M A TE RI

| Injury models
Adult mice were anesthetized with isoflurane or pentobarbital for surgery. The optic nerve of Ccr2 RFP/1 mice was crushed at 1 mm from the optic disc for 5 s using fine forceps, and analyzed by immunohistochemistry 7 days after injury. Experimental autoimmune encephalomyelitis (EAE) was induced by immunizing Ccr2 RFP/1 mice with MOG peptide followed by injection of pertussis toxin as previously described (Bando et al., 2015) . After the appearance of hindlimb paralysis, the ventral white matter of the L4 spinal cord was analyzed by immunohistochemistry. The sciatic nerve was unilaterally transected using scissors and, 7 days after surgery, the sciatic nerve and spinal dorsal horn were analyzed by immunohistochemistry and quantitative real-time PCR (qPCR). For a neuropathic pain model, the spinal L4 nerve of WT and Siglech dtr/dtr mice was unilaterally transected using scissors according to our method described previously (Kobayashi, Konishi, Sayo, Takai, & Kiyama, 2016) , and pain testing, immunohistochemistry and qRT-PCR were performed 1, 3, 7, and 14 days after surgery.
| Ablation of microglia
DT (50 mg/kg) (Sigma Aldrich) was intraperitoneally administrated to P7 or adult Siglech dtr/dtr mice. For the nerve-injury model, the sciatic nerve of adult Siglech dtr/dtr mice was unilaterally transected 7 days before DT administration. Brains, spinal cords and sciatic nerves were processed for immunohistochemistry 2 days after DT administration.
| Immunohistochemistry
Immunohistochemistry was performed according to our previously described method with slight modification (Konishi et al., 2007) . Mice were perfused with Zamboni's fixative (0.1 M phosphate buffer containing 2% paraformaldehyde and 0.2% picric acid), and then brains, the L4 level of spinal cords, optic and sciatic nerves were dissected.
Postfixation was avoided in this study because over-fixation signifi- AB_632234). Characterization of the polyclonal anti-Siglec-H antibody used in the present study was described in our previous study (Zhang et al., 2006 
| qPCR
Cerebral cortex was collected from E17, P0, P7, P14, P28 and 8W WT, and 8W Siglech dtr/dtr mice (n 5 3). L4 spinal dorsal horn and sciatic nerve were taken from WT mice 7 days after sciatic nerve transection (n 5 3). L4 spinal dorsal horn was dissected from WT and Siglech dtr/dtr mice, 0 (naive), 1, 3, 7 and 14 days after L4 nerve transection (n 5 3).
mRNA was purified from tissues using the acid guanidine iso-thiocyanate/phenol/chloroform extraction method, and converted to cDNA by SuperScript III (Thermo Fisher Scientific). qPCR was performed using
StepOnePlus (Applied Biosystems) with Fast SYBR Green Master Mix (Applied Biosystems): 1 cycle of 958C for 20 s, 40 cycles of 958C for 3 s, and 608C for 30 s. Primers were as follows; glyceraldehyde-3-phosphate dehydrogenase (Gapdh) (sense 5 0 -TGACGTGCCGCCTGGAGAAA-
, and transforming growth factor (TGF)-b1 (Tgfb1)
. Amplified PCR samples were subjected to melting analysis to confirm amplicon specificity. Results were normalized to Gapdh and analyzed using the 2 2DDCt method.
| Behavioral analysis of neuropathic pain
WT and Siglech dtr/dtr mice, 0, 3, 7, and 14 days post L4 spinal nerve transection were analyzed (n 5 4). Mice were individually placed in an opaque chamber with a wire mesh floor. After habituation at least for 30 min, the tip of an Electronic von Frey Anesthesiometer (IITC Life Science) was applied to the plantar surfaces of their hindpaws and the paw withdrawal threshold (PWT) was measured.
| Statistical analysis
All values are expressed as the mean 6 S.E.M. Changes in gene expression and cell numbers were analyzed with the unpaired Student's ttest. PWT data was analyzed by two-way ANOVA with a post hoc Bonferroni test. p < .05 was considered statistically significant.
| R ESU L TS
3.1 | Siglec-H is specifically expressed by microglia in the steady state CNS of adult mice, except for in the choroid plexus
We stained sections of cerebral cortex prepared from adult mice with a polyclonal antibody against Siglec-H ( Figure 1 ) (Zhang et al., 2006) . we confirmed that the Siglec-H antibody did not cross-react with
Siglec-E (Figure 1g-i) . The antibody-antigen specificity was further confirmed using Siglech knock-down mice. In Siglech dtr/dtr mice, an Ires and the gene encoding the DT receptor were knocked into the 3 0 untranslated region of the Siglech gene (Takagi et al., 2011 (Takagi et al., , 2016 . This genetic modification was not expected to affect the expression of Siglech; however, our previous study found that Siglec-H expression was knockeddown in pDCs in the immune system of Siglech dtr/dtr mice. qPCR showed that levels of Siglech mRNA were knocked-down in the cerebral cortex of Siglech dtr/dtr mice (75.1% decrease compared with WT by qPCR, In cortical sections, CD206 1 pvMU were found along medium-or large-sized vessels but not along capillaries (single arrowheads in Figure   2b ), and CD206 1 mMU were found in the meninges (double arrowheads in Figure 2b ) (Galea et al., 2005; Goldmann et al., 2016) . These two types of MU had spindle or round shapes with fewer processes capillaries (Goehler, Erisir, & Gaykema, 2006; Murabe, Nishida, & Sano, 1981; Willis, Garwood, & Ray, 2007) . We defined MU within circumventricular organs as circumventricular organ MU (cvoMU) in this study because cvoMU are different from pvMU in that cvoMU contact capillaries and are assumed to play specific roles, such as forming a sizeselective diffusion barrier around capillaries in circumventricular organs (Goehler et al., 2006; Murabe, Nishida, & Sano, 1981; Willis, Garwood, & Ray, 2007) . In the area postrema, Siglec-H was not detected in 100.0%; corpus callosum: 100.0%; hippocampus: 99.7 6 0.3%; thalamus:
100.0%; cerebellum: 99.8 6 0.2%; medulla: 100.0%; spinal cord: 100.0%) (Supporting Information Figure S1g ), and all Siglec-H 1 cells were Iba1
These results demonstrated that Siglec-H expression was confined to microglia in the steady state CNS except for in the choroid plexus.
| Siglec-H is specifically expressed by microglia in the developing CNS
The recently identified microglia-specific markers, TMEM119 and Sall1, are not specific during mouse development (Bennett et al., 2016; Buttgereit et al., 2016; Harrison et al., 2012 ); therefore, we tested whether Siglec-H is specific for microglia during development (Figure 3 ). Even though microglial numbers in the cerebral cortex were small at E17 (Swinnen et al., 2013) , Siglech mRNA was clearly detected by qPCR at a similar level to Aif1 mRNA (encoding Iba1) (Figure 3a) . Because microglia express Iba1 from an early developmental stage (Hirasawa et al., 2005) , we expected that Siglec-H immunoreactivity could be detected in embryonic microglia by immunohistochemistry. In embryonic mice, it was difficult to immunohistochemically distinguish microglia from mMU or pvMU, because immature microglia also expressed CD206
(data not shown) and were not fully ramified. Although microglia could not be defined clearly by morphology at E17, Siglec-H expression was observed in putative Iba1 1 microglia in parenchyma, but not in some Iba1 1 cells in the meninges, which might correspond to mMU ( Figure   3b-d) . At P7, microglial ramification proceeded and microglia were distinguishable from mMU and pvMU by their morphologies (Figure 3f ).
Siglec-H was detected in ramified microglia in parenchyma whereas putative mMU, which had large cell bodies with few processes, were negative for Siglec-H (Figure 3e-g) . A quantitative study showed that
Siglec-H was expressed by most Iba1 1 cells during development (E17:
96.4 6 0.6%; P0: 95.5 6 0.7%; P7: 98.5 6 1.0%; relative to all Iba1 1 cells in the cerebral cortex beneath the meninges) (Figure 3h ).
| Siglec-H is not expressed by monocytes infiltrating an injured or inflamed nervous system
Circulating CCR2 1 monocytes can enter the nervous system upon neuronal injury or inflammation, and play distinct roles from those of microglia (King et al., 2009; Mildner et al., 2009; Varvel et al., 2016; Yamasaki et al., 2014) . We hypothesized that Siglec-H expression could discriminate resident microglia from infiltrating monocytes, and examined the possibility using an optic nerve injury model (Figure 4a -h). We used In addition to the CNS, we examined the PNS. Peripheral nerve injury causes accumulation of MU in the distal part of the injured nerve, which is necessary for Wallerian degeneration (Chen, Piao, & Bonaldo, 2015) . Although resident MU in peripheral nerves proliferate and contribute to the pool, the main source of accumulated MU is monocytes recruited from the circulation (Beuche & Friede, 1984) . (Figure 5g-i) . These histological data were confirmed by qPCR (Figure 5j,k) . Siglec-H expression was increased concomitantly with Iba1 induction in the dorsal horn after injury (Figure 5j ). In contrast, Siglec-H expression was not induced in the injured nerve although Iba1 expression was markedly increased (Figure 5k ).
Collectively, Siglec-H can be used as a histological marker that distinguishes resident microglia from infiltrating monocytes both in the CNS and PNS, except for a minor population.
| The Siglech locus is suitable for microglia-specific gene targeting
Our histological analyses indicated Siglec-H to be a microglia-specific marker in the nervous system, which prompted us to explore the suitability of the Siglech locus for microglia-specific gene targeting in mice ( Figure 6 ). To this end, we used Siglech dtr/dtr mice, in which Siglec-H 1 cells express the DT receptor and can be ablated by systemic DT administration (Takagi et al., 2011) . After peritoneal injection of DT into adult Siglech dtr/dtr mice, a significant number of microglia in the cerebral cortex was ablated within 2 days (Figure 6a,b) . The number of Iba1 1 /CD206 -microglia decreased to 20.6% (Figure 6c ), while those of CD206 1 pvMU and mMU were unchanged (Figure 6d,e) . We also demonstrated in the area postrema that DT was ineffective at ablating We also demonstrated that Siglech locus-mediated gene targeting had no effects on infiltrating monocytes. We prepared adult Siglech dtr/ dtr mice with sciatic nerve injury and 7 days after surgery DT was administered to the mice and cell ablation rates calculated (Figure 6j that almost all the microglia were ablated in the parenchyma.
| Siglec-H suppressed inflammatory responses of activated microglia
Finally we addressed Siglec-H function using a mouse neuropathic pain model. In this model, transection of the L4 spinal nerve induces microglial activation in the L4 dorsal horn, and the resulting inflammatory responses of activated microglia develop and prolong neuropathic pain (Tsuda, 2017) . In the ipsilateral dorsal horn of the model mice, expression of Siglech mRNA increased after injury with a peak at 3 days (Figure 7a) , when the microglial numbers also reached a peak (Kobayashi et al., 2016) . Siglech mRNA was significantly decreased in the ipsilateral dorsal horn of Siglech dtr/dtr mice compared with WT ( Figure 7a ). Immunohistochemistry demonstrated that Siglec-H protein was expressed in activated Iba1 1 microglia in the ipsilateral dorsal horn of WT mice (Figure 7b-g ). However, Siglec-H immunoreactivity was very low in Siglech dtr/dtr mice (Figure 7h-j) . Thus we assumed that Siglec-H could be functionally impaired in Siglech dtr/dtr mice, and we analyzed the and Iba1 (b, e,h, red), and the merged images (c,f,i) are shown. Images were acquired using the same laser power and sensitivity, and image processing were the same for dorsal horn and sciatic nerve samples (d-f vs. g-i). (j) Expression changes of mRNAs encoding Siglec-H and Iba1 in the dorsal horn 7 days after sciatic nerve transection (n 5 3). The contralateral (contra) and ipsilateral (ipsi) dorsal horns were subjected to qPCR. Results are normalized to Gapdh, and shown as ratios to the contralateral side. Values show the mean 6 S.E.M. (k) Expression changes of mRNAs encoding Siglec-H and Iba1 in the sciatic nerve 7 days after transection (n 5 3). The contralateral (contra) and ipsilateral (ipsi) sciatic nerves were subjected to qPCR. Results are normalized to Gapdh, and shown as ratios to the contralateral side. Values show the mean 6 S.E.M. *p < .005 and **p < 5.0 3 10 24 for upregulation, # p < .05 for downregulation; unpaired 
| D I SCUSSION
In this study, we explored the feasibility of Siglec-H as a specific marker for microglia in the nervous system. We revealed that almost all microglia in the CNS parenchyma expressed Siglec-H, from developmental to mature stages (Figures 1-3 ; Supporting Information Figure S1 ), and the expression was maintained in activated microglia after CNS (Figure 4 Siglech locus for microglia-specific gene manipulation in both mature and developing mice ( Figure 6 ). Collectively, we conclude that Siglec-H is a specific marker that will be highly useful for microglial studies.
Siglec-H is a single-pass transmembrane protein belonging to the CD33-related Siglec family (Macauley, Crocker, & Paulson, 2014) .
Although there are no clear orthologs in human, Siglec-L2 is 42%
homologous and is assumed to be a potential ortholog (Zhang et al., 2006) . Siglec-H is known as a marker for pDCs in the immune system Takagi et al., 2011; Zhang et al., 2006) . Several previous studies employing transcriptome or flow cytometric analyses using isolated cells suggested that Siglec-H was abundantly expressed in microglia compared with peripheral myeloid cells, such as circulating monocytes and peripheral MU (Bedard, Tremblay, Chernomoretz, & Vallieres, 2007; Butovsky et al., 2014; Chiu et al., 2013; Gautier et al., 2012; Hickman et al., 2013) . However, no immunohistochemical studies were performed in the nervous system, and it remained unknown whether Siglec-H was expressed by CNS-associated MU as well as monocytes infiltrating in the nervous system. In this study, we demonstrated that Siglec-H expression was largely confined to microglia (Figures 1-5; Supporting Information Figure S1 ) by using a Siglec-Hspecific antibody (Zhang et al., 2006) , whose antigen-specificity was confirmed by an absorption test (Figure 1d (Greter et al., 2015; Prinz & Priller, 2014; Prinz et al., 2011) . This broader expression makes it difficult to discriminate microglia from other myeloid cells by immunohistochemistry. In addition to these classical markers, Bennett et al. (2016) recently reported a transmembrane protein, TMEM119, as a microglia-specific marker, for which mMU, pvMU and cpMU, and CNS-infiltrating monocytes were negative.
Although the authors demonstrated specificity of TMEM119 expression in microglia, the expression was very low or absent in immature microglia in embryonic and early postnatal mice. Sall1 has also recently been shown to be a microglia-specific transcription factor using
Sall1
GFP and Sall1
CreER knock-in mice (Buttgereit et al., 2016; Koso et al., 2016) . Sall1 expression was highly restricted to microglia in the CNS of adult mice; however, Sall1 expression was abundantly observed in neuronal/glial progenitor cells in embryonic mice (Buttgereit et al., 2016; Harrison et al., 2012) . This is in contrast to Siglec-H because Siglec-H expression was observed in microglia in embryonic and early postnatal mice (Figure 3 ). More recently, Mildner et al. (Mildner et al., 2017) reported that a purinoceptor, P2Y 12 , is detected in microglia but not in pvMU and mMU in the developing human brain. Additionally, previous reports showed that P2Y 12 expression was detected in microglia but not in splenic MU or CNS-infiltrating monocytes by immunohistochemistry in mice (Butovsky et al., 2014; Haynes et al., 2006) .
However, P2Y 12 expression is significantly decreased or diminished in activated microglia (Amadio et al., 2014; Haynes et al., 2006; Mildner et al., 2017) , whereas Siglec-H expression was maintained in microglia activated by CNS (Figure 4 ) and PNS injuries ). Siglec-H expression in microglia. Note that faint signals for Siglec-H are predominantly observed in the endoplasmic reticulum/Golgi apparatus of microglia in Siglech dtr/dtr mice (arrows in h-j, high mag.). Images were acquired using the same laser power and sensitivity, and image processing were the same for WT and Siglech dtr/dtr mice (e-g vs. h-j). Scale bar: 200 mm (b-d), 10 mm (e-j). (k) Expression of mRNA encoding proinflammatory cytokines (TNF-a and IL-1b) but not anti-inflammatory cytokines (IL-10 and TGF-b1) was upregulated in the ipsilateral dorsal horn of Siglech dtr/dtr mice. Ipsilateral L4 dorsal horn was obtained from WT and Siglech dtr/dtr mice at each time point after L4 nerve transection (n 5 3 for each time point), and mRNA expression was analyzed by qPCR. Results are normalized to Gapdh, and are shown as ratios to the nonoperated (naive) value of WT mice. Values show the mean 6 S.E.M. *p < .05, **p < 5.0 3 10
In addition to microglia, Siglec-H was detected in Iba1 1 cells in the choroid plexus (Figure 2m-p (Mildner et al., 2017) .
In addition to the immunohistochemical reliability of Siglec-H, we addressed the feasibility of using the Siglech locus for microglia-specific gene manipulation using Siglech dtr/dtr knock-in mice ( Figure 6 ). Genetic targeting of microglia in mice was performed using the gene loci or promoter/enhancer regions of Itgam (encoding CD11b), Csf1r and Cx3cr1 (Boillee et al., 2006; Jung et al., 2000; Pfrieger & Slezak, 2012; Sasmono et al., 2003) . However, given that these molecules are expressed by a variety of myeloid cells, the effect of the genetic modification will not necessarily be restricted to microglia (Goldmann et al., 2016; Wieghofer et al., 2015) . To circumvent this problem, a new system was established based on the longevity of microglia Parkhurst et al., 2013) . When Cx3cr1 CreER/1 mice are crossed to mice harboring a floxed allele, both microglia and peripheral Cx3CR1 1 cells, including monocytes, undergo recombination upon tamoxifen administration. After an interval of several weeks, microglial recombination persists whereas peripheral Cx3CR1 1 cells are replaced by bone marrow-derived progenitors without recombination. Even with this technique, recombination of mMU and pvMU can be maintained for a long period together with microglia because mMU and pvMU are longlived cells (Goldmann et al., 2016) . Thus finding a microglia-specific gene locus is considered important. Results from the present cell ablation study suggest the usefulness of the Siglech locus for microgliaspecific targeting in the CNS (Figure 6a -l and p-r). Another advantage of using the Siglech locus is a lack of recombination in PNS-infiltrating monocytes (Figure 6j-o) . The present results suggest that a Siglech Cre mouse would be a beneficial tool for future microglial studies.
A previous study using cultured microglia suggested that Siglec-H was a phagocytic receptor for glioma cells (Kopatz et al., 2013) . This is the only report addressing the role of Siglec-H in microglia, and Siglec-H functions in the nervous system, especially in vivo, remain elusive. In the immune system, an anti-inflammatory role of Siglec-H in pDCs has been proposed Puttur et al., 2013; Takagi et al., 2011 Takagi et al., , 2016 ). Therefore, we tested the possibility that Siglec-H also suppressed pro-inflammatory responses of microglia using a mouse neuropathic pain model (Tsuda, 2017) . We found that Siglech knockdown promoted induction of representative pro-inflammatory cytokines in spinal microglia (Figure 7k ) without affecting microglial proliferation (Figure 7l-n) . We further revealed that pain behavior was exacerbated in Siglech knock-down mice (Figure 7o,p) . Taken together,
Siglec-H-mediated signals appeared to act as a suppressor of proinflammatory responses in activated microglia. Siglec-H is proposed to be a cell surface receptor, although ligand(s) remain unidentified Kopatz et al., 2013; Zhang et al., 2006) . The intracellular domain of Siglec-H is very short and Siglec-H is known to form a complex with a transmembrane adaptor protein, DNAX-activating protein of 12 kDa (DAP12), to induce intracellular signals . In parallel with Siglec-H, other transmembrane receptors with short intracellular domains, such as triggering receptor expressed on myeloid cells 2 (TREM2), also bind to DAP12 for signal-transduction (Bouchon, Hernandez-Munain, Cella, & Colonna, 2001 ). We recently revealed that TREM2-mediated signals promoted pro-inflammatory responses of microglia via DAP12 in the ipsilateral dorsal horn and exacerbated neuropathic pain (Kobayashi et al., 2016) . Both Siglec-H and TREM2 are able to make complexes with DAP12 on microglial surfaces. However, TREM2 promotes inflammation whereas Siglec-H suppresses inflammation. This controversy is also reported in the immune system Linnartz-Gerlach, Kopatz, & Neumann, 2014; Turnbull & Colonna, 2007) . Siglec-H and TREM2 are likely to work as an opposing switch for microglial activation via DAP12.
Besides neuropathic pain, TREM2/DAP12-mediated microglial activation is also pivotal for pathogenesis of Alzheimer's disease both in humans and in mouse models of the disease (Guerreiro et al., 2013; Jonsson et al., 2013; Paloneva et al., 2000 Paloneva et al., , 2002 Wang et al., 2015; Zhang et al., 2013) . Therefore, further studies, such as identification of
Siglec-H ligand(s), are needed to reveal the precise molecular mechanisms regulating microglial activity via DAP12.
In conclusion, Siglec-H, together with TMEM119, Sall1 and P2Y 12 , will be useful as "contemporary" markers of mouse microglia throughout developmental, adult and aging stages, in both healthy and injury conditions.
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